{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:35Z","timestamp":1778859035904,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.prro.2017.04.013","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T04:31:08Z","timestamp":1492576268000},"page":"e531-e541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery"],"prefix":"10.1016","volume":"7","author":[{"given":"Andrea L.","family":"Arnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann T.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W.","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2017.04.013_bb0005","first-page":"524","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study","volume":"1","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0010","first-page":"10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2017.04.013_bb0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djg040","article-title":"Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control","volume":"95","author":"Weir","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2017.04.013_bb0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1056\/NEJMra035536","article-title":"Multidisciplinary management of lung cancer","volume":"350","author":"Spira","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2017.04.013_bb0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2017.04.013_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1067\/mtc.2001.112465","article-title":"Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"121","author":"Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","article-title":"Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"25","author":"Rusch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0040","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: A phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2017.04.013_bb0045","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1200\/JCO.2010.30.1143","article-title":"Trimodality therapy for locally advanced non-small-cell lung cancer: A curative approach","volume":"29","author":"Stupp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"van Meerbeeck","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2017.04.013_bb0055","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00428-013-1404-6","article-title":"Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus","volume":"462","author":"Blaauwgeers","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.prro.2017.04.013_bb0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejso.2012.09.002","article-title":"Trimodality therapy for superior sulcus tumours: Evolution and evaluation of a treatment protocol","volume":"39","author":"Vos","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0075","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2011.11.069","volume":"84","author":"Suntharalingam","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2017.04.013_bb0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jtcvs.2008.11.016","article-title":"Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders","volume":"137","author":"Cerfolio","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0085","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.athoracsur.2004.06.102","article-title":"Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer","volume":"78","author":"Cerfolio","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtho.2016.08.136","article-title":"Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation","volume":"12","author":"Arnett","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0003-4975(03)01457-7","article-title":"Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer","volume":"77","author":"Port","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0100","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/JTO.0b013e31821517db","article-title":"Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer","volume":"6","author":"Kozak","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0105","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2967\/jnumed.115.167684","article-title":"18F-FDG PET\/CT of non-small cell lung carcinoma under neoadjuvant chemotherapy: Background-based adaptive-volume metrics outperform TLG and MTV in predicting histopathologic response","volume":"57","author":"Burger","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2017.04.013_bb0110","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1007\/s00330-015-3729-9","article-title":"Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery","volume":"25","author":"Vargas","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.prro.2017.04.013_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2014.04.010","article-title":"Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC","volume":"85","author":"Bahce","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2017.04.013_bb0120","doi-asserted-by":"crossref","first-page":"33587","DOI":"10.1038\/srep33587","article-title":"Comparison of the 7(th) and proposed 8(th) editions of the AJCC\/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery","volume":"6","author":"Jin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.prro.2017.04.013_bb0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2214\/AJR.12.9138","article-title":"PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma","volume":"200","author":"Davison","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.prro.2017.04.013_bb0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","article-title":"Noise considerations for PET quantification using maximum and peak standardized uptake value","volume":"53","author":"Lodge","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2017.04.013_bb0135","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2967\/jnumed.115.155309","article-title":"Prognostic value of pretherapeutic tumor-to-blood standardized uptake ratio in patients with esophageal carcinoma","volume":"56","author":"Butof","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2017.04.013_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13550-016-0174-y","article-title":"An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET","volume":"6","author":"Hofheinz","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prro.2017.04.013_bb0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/2191-219X-3-77","article-title":"The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG","volume":"3","author":"van den Hoff","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prro.2017.04.013_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00259-006-0273-5","article-title":"18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer","volume":"34","author":"Eschmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2017.04.013_bb0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000134474","article-title":"Correlation of PET\/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer","volume":"73","author":"Poettgen","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.prro.2017.04.013_bb0160","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1200\/JCO.2015.65.5167","volume":"34","author":"Pottgen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.6004\/jnccn.2015.0030","article-title":"Value of functional imaging by PET in esophageal cancer","volume":"13","author":"Schmidt","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.prro.2017.04.013_bb0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.nucmedbio.2014.02.006","article-title":"PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients","volume":"41","author":"Burger","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.prro.2017.04.013_bb0175","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtcvs.2015.09.127","article-title":"Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer","volume":"151","author":"Ripley","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/JTO.0b013e3181ce3e5e","article-title":"A systematic review of restaging after induction therapy for stage IIIa lung cancer: Prediction of pathologic stage","volume":"5","author":"de Cabanyes","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2017.04.013_bb0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.athoracsur.2015.03.075","article-title":"Higher versus standard preoperative radiation in the trimodality treatment of stage IIIa lung cancer","volume":"100","author":"Bharadwaj","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.prro.2017.04.013_bb0190","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: A phase 1 dose escalation study","volume":"96","author":"Hepel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850017301200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850017301200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:21:57Z","timestamp":1761819717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850017301200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1879850017301200"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2017.04.013","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2017.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}